Paradigm Biopharmaceuticals Limited PBIGF
0.01 USD 0.00 (+0.00%)
Regular-session close
0.008 Day range 0.008
0.0014 52-week range 0.2744
- YTD
- -94.87%
- 1 year
- -94.49%
Included in Essentials and up
Sign in to see Fair value
Discounted cash flow estimates against the price, and the P/E against its industry and sector.
Included in Essentials and up
Sign in to see Head count and owner earnings
Employees by annual report and the cash the business earns for its owners.
Included in Essentials and up
Sign in to see P/E against peers
The price to earnings ratio beside the closest competitors and their median.
Included in Essentials and up
Sign in to see Cash flow and returns
How profit turns into free cash flow, and the returns on equity, assets and capital.
Financial health
Altman Z-Score
-19.48 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
Valuation
P/E -1.2×
P/S 883×
P/B 20.4×
P/FCF -1.6×
EV/EBITDA -1.0×
EV/Sales 784×
FCF Yield -61.8%
Profitability
Gross Margin -102.8%
Operating Margin -76248.1%
Net Margin -70283.8%
ROE -1623.0%
ROIC -484.1%
ROA -184.4%
Growth (YoY)
Revenue 53.6%
Operating Income -166.6%
EPS (diluted) -168.0%
Free Cash Flow -172.8%
Financial Health
Current Ratio 1.1×
Quick Ratio 1.1×
Debt / Equity 2.2×
Net Debt / EBITDA 0.1×
Interest Coverage -24.8×
Dividends
Dividend Yield 0.0%
Payout Ratio 0.0%
Annual · latest fiscal year ends 2026-06-30
